Healios K.K. (OTCMKTS:HLOSF) Short Interest Update

Healios K.K. (OTCMKTS:HLOSF) was the recipient of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 4,800 shares, a decrease of 92.4% from the October 31st total of 62,900 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days.

Healios K.K. Stock Performance

HLOSF stock remained flat at 1.20 during midday trading on Wednesday. Healios K.K. has a twelve month low of 0.93 and a twelve month high of 1.73. The company’s 50 day simple moving average is 1.55 and its 200-day simple moving average is 1.34.

Healios K.K. Company Profile

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease.